114446-48-9

Basic information

• Product Name: Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethyl)-, (R)-
• CAS NO: 114446-48-9
• Molecular Formula: C16H14ClF3O
• Molecular Weight: 314.735
• Mol File: 114446-48-9.mol
• Article Data: 6

Chemical Properties

• CAS DataBase Reference: Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethyl)-, (R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethyl)-, (R)-(114446-48-9)
• EPA Substance Registry System: Benzene, 1-(3-chloro-1-phenylpropoxy)-4-(trifluoromethyl)-, (R)-(114446-48-9)

Safety Data

• Hazardous Substances Data: 114446-48-9(Hazardous Substances Data)

Upstream product

• 402-45-9 4-hydroxybenzotrifluoride 
• 100306-34-1 3-chloro-1-phenylpropanol 
• 402-45-9 α,α,α-trifluoro-p-cresol 
• 936-59-4 3-chloropropiophenone 
• 18776-12-0 3-chloro-1-phenyl-propan-1-ol 
• 293322-40-4 3-Cloro-1-phenylpropyl butanoate 
• 141987-54-4 1-Phenyl-3-chlor-propyl-monochloracetat 
• 142037-19-2 Chloro-acetic acid (S)-3-chloro-1-phenyl-propyl ester 
• 444-30-4 2-(trifluoromethyl)phenol 

Downstream Products

• 878663-12-8 (R)-1-phthalimido-3-(4-trifluormethyl-phenoxy)-3-phenyl-propane 
• 878663-15-1 C₃₇H₄₂F₃N₃O₄ 
• 114247-09-5 (R)-fluoxetine hydrochloride 
• 54910-89-3 (R)-fluoxetine 

Relevant articles and documents

Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression

Multi-target compounds where more than one functional activity is incorporated into the same molecule may have advantages in treating disease states. Selective serotonin re-uptake inhibitors (SSRIs)a (i.e., (R)- and (S)-norfluoxetine) were chemically linked to a PDE4 inhibitor via a five carbon bridge. The new dual PDE4 inhibitor/SSRIs (i.e., (R)-8 and (S)-8) showed moderately potent but highly selective serotonin re-uptake inhibition (IC50 values of 173 and 42 nM, respectively) in vitro. The dual PDE4 inhibitor/SSRIs (R)-8 and (S)-8 also inhibited PDE4D2 (i.e., Ki values of 106 and 253 nM, respectively). Due to the synergistic functional activity, PDE4 inhibitor/SSRIs may be effective in treating diseases such as depression.

An efficient route to enantiomerically pure antidepressants: Tomoxetine, nisoxetine and fluoxetine

Both enantiomers (R)- and (S)-3-chloro-1-phenyl-1-propanol can be obtained conveniently by an efficient enzymatic resolution process. They can be converted via enantioconvergent routes into all enantiomers of the important antidepressants (R)- and (S)-Tomoxetine, Fluoxetine and Nisoxetine.

Novel process of producing phenyl or substituted phenylalkylamine pharmaceutical agents and novel chiral intermediates of high enantiomeric purity useful therein

A process for producing the optically pure (+)- or (-) isomer of a phenyl- or substituted- phenylalkanolamine compounds having pharmacologic activity without the need for resoltuion processes ad novel intermediates useful in the process including optically pure haloalcohols are provided.